Erratum: Behandlung im Voraus planen – Bedeutung für die Intensiv- und Notfallmedizin

Anästhesiol Intensivmed Notfallmed Schmerzther 2018; 53: e1-e1
DOI: 10.1055/a-0591-7094

Georg Thieme Verlag KG Stuttgart · New York

Article in Thieme eJournals:
Table of contents  |  Full text

http://ift.tt/2HI4A09

Survival of dental implants placed in HIV-positive patients: a systematic review

Publication date: Available online 16 March 2018
Source:International Journal of Oral and Maxillofacial Surgery
Author(s): C.A.A. Lemos, F.R. Verri, R.S. Cruz, J.F. Santiago Júnior, L.P. Faverani, E.P. Pellizzer
No consensus has been reached on the use of dental implants in human immunodeficiency virus (HIV)-positive patients. This systematic review evaluated dental implants in HIV-positive patients in terms of implant survival and success rates, marginal bone loss, and complications. The review was conducted according to the PRISMA checklist. Two independent reviewers performed a comprehensive search of the PubMed/MEDLINE, Scopus, and Cochrane Library databases for studies published until October 2017. Six studies were selected for review. In total, 821 implants were placed: 493 in 169 HIV-positive patients, and 328 in 135 HIV-negative patients. The mean duration of follow-up was 47.9 months. Weighted mean survival rate, success rate, and marginal bone loss values were calculated for the HIV-positive patients. Mean survival and success rates at the patient level (according to the number of patients) were 94.76% and 93.81%, respectively; when calculated at the implant level (according to the number of implants), these rates were 94.53% and 90.37%, respectively. Mean marginal bone loss was 0.83mm at the patient level and 0.99mm at the implant level. Thus, dental implants are suitable for the rehabilitation of HIV-positive patients with controlled risk factors and normal CD4+ cell counts.



http://ift.tt/2FR5ZRA

The multidimensional burden of atopic dermatitis: an update

Publication date: Available online 16 March 2018
Source:Annals of Allergy, Asthma & Immunology
Author(s): Alanna C. Bridgman, Julie K. Block, Aaron M. Drucker




http://ift.tt/2tV5CDZ

Mycoplasma pneumoniae induces allergy by producing p1-specific IgE

Publication date: Available online 16 March 2018
Source:Annals of Allergy, Asthma & Immunology
Author(s): Qing Ye, Jian-hua Mao, Qiang Shu, Shi-qiang Shang
BackgroundOur previous study found that most of MPP patients had elevated serum total IgE levels.ObjectiveThe purpose of this paper is to determine components of mycoplasma pneumoniae that can cause IgE increase in children, and to clarify its specific mechanism.MethodsThe components of MP cells were isolated by serum IgE from patients with MP pneumonia (MPP). These components obtained through the prokaryotic expression were used as allergens to detect the proportion of allergen-specific IgE produced in MPP patients, and the clinical characteristics and related immune parameters of these patients who produced this allergen-specific IgE were also analyzed. In addition, cell experiment was used to verify the biological effect of these components in vitro.ResultsP1-specific IgE was detected in serum of MPP children. An about 24-kDa polypeptide of P1 protein was obtained through prokaryotic expression purified by nickel agarose affinity chromatography. Approximately 9.2% of MPP patients produced IgE against this polypeptide of P1 protein, which was more likely to be produced in MPP patients with no history of allergies or family history of allergy-related diseases. P1-specific IgE-positive MPP patients had more severe clinical symptoms, with excessive secretion of IL-4 and IL-5 and over-differentiation of Th0 cells into Th2 cells. Tests also demonstrated that the P1 protein stimulated excessive secretion of IL-4 and IL-5 in PBMCs from the peripheral blood of healthy donors.ConclusionMP is not only an infectious agent but also an allergen for certain individuals. The P1 protein of MP can induce the production of P1-specific IgE.



http://ift.tt/2piDy8Q

Environmental exposure to peanut and the risk of an allergic reaction

Publication date: Available online 16 March 2018
Source:Annals of Allergy, Asthma & Immunology
Author(s): Matthew Greenhawt
The purpose of this review is to detail the medical evidence surrounding such potential risk of reaction to peanut in public venues, focusing on educational settings and commercial aircraft, and to review the medical evidence and best-practices regarding potential risk mitigating strategies.



http://ift.tt/2DA3hOx

Aeromonas caviae mimicking Vibrio cholerae infectious enteropathy in a cholera-endemic region with possible public health consequences: two case reports

Aeromonas species have been documented to yield false positive results in microbiological tests for Vibrio cholerae. They share many biochemical properties with Vibrio species, with which they were jointly classi...

http://ift.tt/2pjAfOP

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience

Publication date: May 2018
Source:Oral Oncology, Volume 80
Author(s): Corey C. Foster, James M. Melotek, Ryan J. Brisson, Tanguy Y. Seiwert, Ezra E.W. Cohen, Kerstin M. Stenson, Elizabeth A. Blair, Louis Portugal, Zhen Gooi, Nishant Agrawal, Everett E. Vokes, Daniel J. Haraf
ObjectivesDefinitive chemoradiation (CRT) for oral cavity squamous cell carcinoma (OC-SCC) is often criticized for poor efficacy or toxicity. We describe a favorable 20-year experience of primary CRT for locally-advanced OC-SCC.Materials and MethodsPatients with locally-advanced, stage III/IV OC-SCC receiving primary concomitant CRT on protocols from 1994 to 2014 were analyzed. Chemotherapy included fluorouracil and hydroxyurea with other third agents. Radiotherapy (RT) was delivered once or twice daily to a maximum dose of 70–75 Gy. Intensity-modulated RT (IMRT) was exclusively used after 2004. Progression-free survival (PFS), overall survival (OS), locoregional control (LRC), and distant control (DC) were calculated by the Kaplan-Meier method and compared across treatment decades using the log-rank test. Rates of osteoradionecrosis (ORN) requiring surgery were compared across treatment decades using the Chi-square test.Results140 patients with locally-advanced OC-SCC were treated with definitive CRT. Of these, 75.7% had T3/T4 disease, 68.6% had ≥N2 nodal disease, and 91.4% had stage IV disease. Most common primary sites were oral tongue (47.9%) and floor of mouth (24.3%). Median follow-up was 5.7 years. Five-year OS, PFS, LRC, and DC were 63.2%, 58.7%, 78.6%, and 87.2%, respectively. Rates of ORN and long-term feeding tube dependence were 20.7% and 10.0%, respectively. Differences in LRC (P = 0.90), DC (P = 0.24), PFS (P = 0.38), OS (P = 0.10), or ORN (P = 0.38) were not significant across treatment decades.ConclusionDefinitive CRT is a viable and feasible strategy for organ preservation for patients with locally-advanced OC-SCC.



http://ift.tt/2pit4FG